Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides

Wilson, Lynn D.; Jones, Glenn; Kim, David; Rosenthal, Don; Christensen, Inger; Edelson, Richard L.; Heald, Peter; Kacinski, Barry M.

doi:10.1067/mjd.2000.105510

Cited by 109 publications

(62 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, patients without profound immune deficiencies, reflected by normal or near-normal cytotoxic T-cell and CD4/CD8 values and the absence of prior exposure to systemic chemotherapy, may be more likely to respond to therapy [310,313]. While effective as monotherapy, ECP has also been combined with other therapeutic strategies, including interferon, bexarotene and TSEBT [292,302,312,[315][316][317].…”

Section: Extracorporeal Photophoresismentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

Section: Extracorporeal Photophoresismentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

show abstract

“…They also evaluated erythrodermic (T4) patients treated with TBSEB and concurrent ECP or TBSEB only. 34 Patients with CR had a disease-free survival (DFS) of 63%. Within this group, DFS was 49% for patients who received TBSEB alone versus 81% for patients who had received TBSEB and ECP.…”

Section: Photopheresis and Combined Immunomodulatory Therapymentioning

confidence: 99%

“…33 Patients with T4 stage erythrodermic MF may also have prolonged remissions when TBSEB is combined with extracorporeal photochemotherapy (ECP) for disease palliation. 34 Side effects of TSEB include erythema, swelling, exfoliation, tenderness, blister formation, alopecia, anhidrosis, and nail loss. 35 Effects are usually transient although hair and nail thinning may persist and skin aging is common.…”

Section: Local and Total Skin Electron Beam Therapymentioning

confidence: 99%

Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome

Duvic

2015

Hematology

View full text Add to dashboard Cite

“…Prolonged response rates have been reported when combined with INF-α, bexarotene, granulocyte colony-stimulating factor (G-CSF), or TESBT. [23][24][25] There have been few adverse events related to ECP treatment, including catheterrelated infection and hypotension caused by volume shifts. Alemtuzumab Alemtuzumab (CamPath ® ) is a humanized IgG 1 MoAb that targets the CD52 antigen abundantly expressed on normal and malignant B and Tcells, but not on hematopoietic stem cells.…”

Section: Extracorporeal Photopheresismentioning

confidence: 99%

Primary Cutaneous T-Cell Lymphomas

Rosen¹,

Querfeld²

2006

Hematology

View full text Add to dashboard Cite

Primary cutaneous T-cell lymphomas (CTCLs) encompass a clinically and biologically heterogeneous group of non-Hodgkin lymphomas (NHLs) defined by clonal proliferation of skin-homing malignant T lymphocytes and natural killer cells. They account for up to 75% to 80% of all cutaneous lymphomas. The current WHO-EORTC classification of cutaneous lymphomas with primary cutaneous manifestations lists 13 entities. The most common subtypes-mycosis fungoides, Clinical featuresMF is typically a chronic, slowly progressing disease with an indolent evolution. The disease is characterized by the development of patches, plaques or tumors (Figure 1; see Color Figures, page 513). The typical patch is a flat, annular, scaly skin lesion mimicking eczema, psoriasis, or dermatophyte infection. It is often erythematous to violaceous in color and has a predilection for sun-protected areas, including the lower abdomen, upper thighs, buttocks, and female breasts. These initial lesions may spontaneously regress and recur. Patches are highly variable and can give rise to or coexist with plaques, which are raised, palpable skin lesions (Figure 1a and 1b

show abstract

Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides

Cited by 109 publications

References 16 publications

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome

Primary Cutaneous T-Cell Lymphomas

Contact Info

Product

Resources

About